Literature DB >> 19954815

End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program.

Nabeen C Nayak1, Nandini Vasdev, Sanjiv Saigal, Arvinder S Soin.   

Abstract

In a proportion of liver cirrhosis, the etiology continues to remain elusive. It is uncertain whether and to what extent cirrhosis evolving from nonalcoholic fatty liver disease contributes to this group of cryptogenic cirrhosis because the clinicopathologic features of nonalcoholic fatty liver disease cirrhosis are largely unknown. We explored these facets by examining the explant livers and clinical data in living donor liver transplant recipients. Among 103 adult liver transplant recipients with different types of chronic liver disease, 30 had a pre-liver transplant diagnosis of cryptogenic cirrhosis. A final categorization of the native liver disease was attempted in these cases on the basis of detail pathomorphological findings in adequately sampled explant liver correlated with careful review of pre-liver transplant clinical data. Of the 30 cryptogenic cirrhosis cases, 19 (63.3%) finally labeled as nonalcoholic fatty liver disease cirrhosis showed histologic features in several respects different from those reported for the early and established phases of nonalcoholic fatty liver disease. Steatosis was infrequent and focal or even absent, whereas variable grades of Mallory hyaline and inflammation were consistently present. Ductular proliferation and hydropic change of hepatocytes were also frequent. Only 9 (47%) of the 19 cases had nonalcoholic fatty liver disease associated risk factors like diabetes and obesity. It was concluded that appreciation of quantitative and qualitative differences in hepatic morphology between the cirrhotic and the early/established stage of nonalcoholic fatty liver disease will help in making a correct diagnosis of nonalcoholic fatty liver disease cirrhosis in the proper clinical setting. When appropriate criteria are used, nonalcoholic fatty liver disease appears to account for close to two thirds of cases currently labeled as cryptogenic cirrhosis. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19954815     DOI: 10.1016/j.humpath.2009.06.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  19 in total

1.  Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.

Authors:  Palanivelu Praveenraj; Rachel M Gomes; Saravana Kumar; Purushothaman Karthikeyan; Annapoorni Shankar; Ramakrishnan Parthasarathi; Palanisamy Senthilnathan; Subbiah Rajapandian; Chinnusamy Palanivelu
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

2.  Non-cirrhotic portal fibrosis related end stage liver disease in adults: evaluation from a study on living donor liver transplant recipients.

Authors:  Sanjiv Saigal; Nabeen C Nayak; Deepali Jain; Vinay Kumaran; Ravi Mohanka; Neeraj Saraf; Amit Rastogi; Naimesh Mehta; Samiran Nundy; Arvinder Soin
Journal:  Hepatol Int       Date:  2011-01-12       Impact factor: 6.047

3.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

4.  Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism.

Authors:  Brenda de Oliveira da Silva; Luciane Carla Alberici; Letícia Ferreira Ramos; Caio Mateus Silva; Marina Bonfogo da Silveira; Carlos R P Dechant; Scott L Friedman; Kumiko Koibuchi Sakane; Letícia Rocha Gonçalves; Karen C M Moraes
Journal:  Int J Biochem Cell Biol       Date:  2018-03-07       Impact factor: 5.085

Review 5.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

6.  Glitazones for human nonalcoholic steatohepatitis.

Authors:  Raluca Pais; Ioana Moraru; Vlad Ratziu
Journal:  Therap Adv Gastroenterol       Date:  2011-09       Impact factor: 4.409

Review 7.  Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.

Authors:  Ajay Duseja; Shivaram P Singh; Vivek A Saraswat; Subrat K Acharya; Yogesh K Chawla; Subhankar Chowdhury; Radha K Dhiman; Rohinivilasam V Jayakumar; Kaushal Madan; Sri P Misra; Hrudananda Mishra; Sunil K Modi; Arumugam Muruganathan; Banshi Saboo; Rakesh Sahay; Rajesh Upadhyay
Journal:  J Clin Exp Hepatol       Date:  2015-03-06

Review 8.  Nonalcoholic fatty liver disease in India - a lot done, yet more required!

Authors:  Ajay Duseja
Journal:  Indian J Gastroenterol       Date:  2010-12-30

9.  Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific.

Authors:  Roslyn Vongsuvanh; David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2013-07-31       Impact factor: 6.047

10.  Non-alcoholic Fatty Liver Disease: East Versus West.

Authors:  Swastik Agrawal; Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.